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Purpose: To evaluate ocular hypertension (OHT) after Ozurdex injection to determine the incidence of OHT, therapy for OHT, and any associative factors such as diagnosis, underlying glaucoma and therapy, or sequential Ozurdex injection(s).
Methods: Retrospective consecutive case series with patients receiving one or more intravitreal Ozurdex implantations at a tertiary care academic center. Ocular hypertension was defined as a single measurement of $30 mmHg or an increase of $10 mmHg from baseline.
Results: Ninety-four injections in 52 patients (59 eyes) were reviewed. Forty eyes received a single injection, and 19 eyes received multiple injections. Ocular hypertension developed in 14 patients (26.9%). Thirteen patients (25%) had preexisting glaucoma or suspicion of glaucoma, and 6 of these developed OHT. Glaucoma eye drops were initiated after 13 injections (13.8%). Invasive surgery for glaucoma was required in 3 patients (3.2%): all had glaucoma or suspicion of glaucoma (one case was related to neovascular glaucoma and unlikely related to steroid response after Ozurdex). There was no difference in relative intraocular pressure increase (i.e., difference between final follow-up or subsequent intravitreal injection vs. baseline) between single versus multiple Ozurdex injections (P = 0.883).
Conclusion: Patients (26.9%) who received Ozurdex developed OHT. Glaucoma or glaucoma-suspicion factors were present in all patients who required invasive surgery for glaucoma. A greater proportion of patients who received multiple injections had an intraocular pressure elevation, but the relative intraocular pressure increase was not significant.
RETINA 37: [1345] [1346] [1347] [1348] [1349] [1350] [1351] 2017 T he use of intravitreal corticosteroids for treatment of posterior segment diseases has increased significantly over the last decade. [1] [2] [3] [4] [5] A commonly recognized complication of intravitreal steroids is ocular hypertension (OHT), which can occur immediately after a direct increase in intraocular volume, or weeks to months later due to the steroid effects on aqueous drainage. 6 Risk factors included preexisting glaucoma, higher baseline intraocular pressure (IOP), younger age, OHT after previous injection, uveitis, and higher steroid dosage. Identification of secondary OHT after intravitreal steroid use is important, because OHT in most cases is initially asymptomatic, and can result in permanent loss of vision if left untreated.
Dexamethasone implant (Ozurdex; Allergan Inc, Irvine, CA) is a free-floating device inserted into the vitreous cavity through a 23-gauge needle and releases corticosteroid for up to 6 months. 7 The implant is bioerodible resulting in a gradual sustained release of medication after the polymer undergoes hydrolysis to carbon dioxide and water, which results in complete dissolution of the device within the vitreous cavity. 7, 8 Animal studies show that a peak concentration of dexamethasone in the vitreous at 2 months is followed by a relatively rapid decline between 2 and 3 months. 7 The intravitreal concentration then reaches a steady state through 6 months. 9 The pharmacokinetics of 0.7 mg Ozurdex is similar in nonvitrectomized and vitrectomized eyes. [10] [11] [12] The US Food and Drug Administration approved 0.7 mg Ozurdex for the treatment of macular edema after retinal vein occlusions in June 2009, for noninfectious posterior uveitis (NIPU) in September 2010 and for diabetic macular edema (DME) in September 2014. 13, 14 Ocular hypertension was defined as an IOP $25 mmHg or $10 mmHg from baseline in previous large multicentered studies involving Ozurdex. [1] [2] [3] Many clinical trials have exclusion criteria which may not accurately reflect the complexity of patients seen routinely in a real-world clinical setting. For example, some of the exclusion criteria included visual acuity worse than 20/200, history of vitrectomy surgery, use of corticosteroids (systemic, periocular, or intraocular) within 30 days of enrollment, moderate or severe glaucoma, poorly controlled hypertension, and poorly controlled diabetes. 2 In this report, we evaluated the incidence of OHT after single and multiple Ozurdex injections. We investigated the occurrence in those with and without a history of glaucoma, as well as the mean time of follow-up at which an elevated IOP may occur across various vitreoretinal diseases.
Materials and Methods
This was a retrospective consecutive single-center study at a tertiary care academic center. After University of Iowa institutional review board approval was obtained, we evaluated all patients who underwent Ozurdex injection in one or both eyes between October 2009 and April 2014. Only those patients who had at least 1 month of follow-up were included. The final follow-up point was either a maximum of 14 months or the nearest time to subsequent Ozurdex injection.
Baseline clinical factors included clinical indication for injection, history of known primary or secondary glaucoma (e.g., primary open-angle glaucoma, uveitic glaucoma, neovascular glaucoma, or angle-closure glaucoma), or suspicion of glaucoma (e.g., history of OHT defined as a single preinjection IOP measurement $23 mmHg, steroid-responsive IOP elevation, optic nerve asymmetry defined as a cup-to-disc ratio difference $0.3, and/or optic nerve cupping defined as a cup-to-disc ratio $0.6 in either eye (collectively defined as "risk of glaucoma" for the remainder of the manuscript).
Outcome measures included the greatest difference of IOP between the baseline (time of Ozurdex injection) and at subsequent follow-up visit after Ozurdex injection; the proportion of patients with OHT at any point after an Ozurdex injection; and the proportion of patients requiring medical or surgical intervention for OHT. Laser-destructive intervention such as trabeculoplasty or diode laser cyclophotocoagulation was considered surgical intervention. The number of eyes with OHT was defined as either a single measurement of $30 mmHg or an increase of $10 mmHg from baseline. Intraocular pressure was obtained by Tonopen tonometry (Reichert Tono-Pen XL, Reichert, Inc., Depew, NY) at each visit. The type of surgical glaucoma intervention was determined by the glaucoma specialist.
Descriptive statistics (frequencies and proportions for discrete variables) were used to determine patient characteristics and the occurrence of events, such as the need for IOP-lowering medical therapy or surgical procedures. Continuous descriptive statistics (mean, median, SD, range) were determined for measures of IOP (mmHg). The mean change in IOP from preoperative to postoperative visits for implant placement was analyzed using the 2-tailed t-test and Tukey's multiple comparison test, where P ,0.05 was considered statistically significant. The distribution of eyes that experienced an IOP spike between different groups was analyzed using the 2-tailed Fisher's exact test, where P ,0.05 was considered statistically significant.
Results

Demographics and Clinical Indications
A total of 105 Ozurdex implants were administered to eyes of 58 patients between October 2009 and April 2014. Demographic characteristics, including their clinical indication for Ozurdex injection, are listed in Table 1 . Eight patients had bilateral disease, of which one patient had bilateral branch retinal vein occlusion, three patients had bilateral DME, and four patients had The average IOP across all patients who received Ozurdex injection was plotted against the various follow-up intervals ( Figure 1A ). The average change in IOP (between final follow-up and baseline) across all patients was an increase of 4.8 mmHg. The greatest IOP elevation was seen at the 1.5-month to 2.5-month follow-up interval. The average IOP separated by various clinical indications show a general upward trend in the early postinjection follow-up time period, followed by a return to baseline ( Figure 1B ). There was no statistically significant difference between relative IOP increase from baseline among the various clinical indications for Ozurdex (Table 2) .
Fourteen patients (27 injections) received Ozurdex for branch retinal vein occlusion, and 2 patients had risk of glaucoma. There were 5 instances (4 patients) of an IOP elevation $10 mmHg from baseline, of whom 1 patient had risk of glaucoma. There was 1 instance from 1 patient (with no history of glaucoma) who had a single IOP measurement of $30 mmHg at follow-up. Three patients were started on IOPlowering medication, none of whom had any risk of glaucoma. No patients with branch retinal vein occlusion required surgery for glaucoma.
Nine patients (13 injections) received Ozurdex for central retinal vein occlusion (CRVO), and 3 patients had risk of glaucoma. There were 2 instances (2 patients) who had an IOP elevation $10 mmHg from baseline; both had a history of risk of glaucoma. There were 3 instances (2 patients) who had a single IOP measurement of $30 mmHg; both had a history of risk of glaucoma. Two patients, both with a history of risk of glaucoma, were started on IOP-lowering medication. Two patients, both with a history of risk of glaucoma, required surgery for glaucoma: one patient had a history of steroid-induced OHT after intravitreal triamcinolone injections, who was treated with trabectome surgery; the second patient had a history of ischemic CRVO with neovascular glaucoma (less likely related to steroid response after Ozurdex) which was managed with a glaucoma drainage device.
Nine patients (20 injections) received Ozurdex for DME, and 2 patients had risk of glaucoma. There was 1 patient who had a history of risk of glaucoma who experienced an IOP elevation $10 mmHg from baseline. There were no instances of an IOP measurement of $30 mmHg. No patients were initiated on IOP-lowering medications, and no patients required surgery for glaucoma. Fourteen patients (24 injections) received Ozurdex for NIPU, 3 patients had risk of glaucoma. There were 5 instances (4 patients) who had an IOP elevation $10 mmHg from baseline, none had a history of risk of glaucoma. There were 4 instances (2 patients) who had a single IOP measurement of $30 mmHg at follow-up, and neither had a history of risk of glaucoma. Four patients, none with a history of risk of glaucoma, were initiated into IOP-lowering medication. No patients with NIPU required surgery for glaucoma.
Six patients (10 injections) received Ozurdex for cystoid macular edema after retinal detachment repair, epiretinal membrane peeling, or surgery for cataract; 3 patients had risk of glaucoma. There were 2 instances (2 patients) who had an IOP elevation $10 mmHg from baseline IOP, of which 1 patient had a history of risk of glaucoma. There were 2 instances (2 patients) who had a single IOP measurement of $30 mmHg at follow-up, of which one had a history of risk of glaucoma. Two patients were started on IOP-lowering medication, of which one had a history of risk of glaucoma. One patient, who had a known history of primary openangle glaucoma and prior glaucoma drainage device, required invasive surgery for glaucoma by way of transscleral cyclophotocoagulation.
History of Glaucoma or Suspicion of Glaucoma
A total of 13 patients (22.4%, 14 eyes) had prior glaucoma or suspicion of glaucoma(collectively "risk of glaucoma"): 1 patient had primary open-angle glaucoma, 1 had neovascular glaucoma from an ischemic CRVO, 1 had uveitic glaucoma (with a history of trabeculectomy surgery 3 years prior), 5 had a history of steroid-induced glaucoma, 2 were suspected to have glaucoma based on optic nerve cupping, and 3 patients had a history of ocular hypertension. There were 14 instances (14.9%; 13 patients) with an IOP elevation of $10 mmHg from baseline, of 5 patients (38.5%) had a risk of glaucoma (P = 0.5443, Figure 2A ). There were 10 instances (10.6%; 7 patients) of an IOP elevation of 30 mmHg or greater, of whom 3 patients (42.9%) had a risk of glaucoma (P = 0.0696, Figure 2B ). Glaucoma eye drops were initiated after 13 injections (13.8%; 11 patients), and only 2 patients (18.2%) had a risk of glaucoma. Invasive surgery for glaucoma was required after 3 injections (3.2%; three patients), of whom all three patients had a history of risk of glaucoma.
Single Versus Multiple Ozurdex Injections
A subset of 18 patients (34.6%; 54 injections in 19 eyes) received 2 or more (multiple) consecutive Ozurdex injections. Of these patients, nine received two injections, three received three injections, three received four injections, and three patients received five injections. Among those who received multiple injections, the average time between injections for all patients was 8.4 months (or 252.6 days). When any outliers of 9 months or beyond between injections were excluded (i.e., 6 patients who had 11, 11, 12, 13, 20 , and 48 months between injections), the average time was 5.4 months (or 162 days).
Seven of 40 eyes (17.5%) that received a single Ozurdex injection experienced a relative IOP elevation of $10 mmHg from the time of the first Ozurdex injection. By contrast, 7 of 19 eyes (36.8%) that received multiple consecutive Ozurdex injections experienced a follow-up IOP elevation of $10 mmHg relative to the time immediately before the Ozurdex injection ( Figure 3A) . Three of the seven of these eyes experienced OHT at the time of their initial injection, whereas the remainder were at the time of subsequent injection. The Kaplan-Meier survival curve between the 2 groups demonstrates that the greatest risk for IOP elevation is in the 1.5-month to 2.5-month interval (Figure 3B) . No long-term risk beyond 4-month follow-up was appreciated. When mean IOP elevation (difference between maximum follow-up and the time of the first Ozurdex injection) was compared between single versus multiple Ozurdex injections ( Figure 3C ), no statistically significant difference was observed (P = 0.883).
Discussion
Common side effects of intraocular corticosteroids may include cataract and OHT. The latter is usually mild to moderate, but transient. The peak of IOP is between the 1.5-month to 2.5-month interval, and we observed normalization in IOP at the 5-month to 6.5-month follow-up. These findings were consistent with the pharmacokinetics in animal studies. 10 Among those who had an increase in IOP, topical treatment was sufficient in a majority of cases. Only three patients required invasive surgery for glaucoma, all of whom had glaucoma or its suspicion factors, for which Ozurdex may have partly contributed to the need for more advanced management of glaucoma. The patient who required a glaucoma drainage device had a history of ischemic CRVO and neovascularization of the iris. This patient's elevated IOP is likely multifactorial and may have been partly or wholly related to the underlying diagnosis which was also treated by panretinal photocoagulation. A second patient who required trabectome surgery received one prior Ozurdex injection for nonischemic CRVO, but had a known history of steroid-induced OHT. And lastly, a third patient who received transscleral cyclophotocoagulation laser treatment 1 month after the first Ozurdex injection had a known history of primary open-angle glaucoma, and prior surgery for glaucoma 1 year before Ozurdex injection.
Some studies define "IOP elevation" as an increase of at least 5 mmHg from baseline at follow-up or an isolated measurement of .25 mmHg. We used four commonly used parameters to more precisely capture such adverse events: IOP elevation $10 mmHg from baseline IOP, $30 mmHg at any visit, the initiation of IOP-lowering drops, and the number of patients requiring incisional surgery for glaucoma. The percentages for these in our study were 14.9%, 10.6%, 13.8%, and 3.2%, respectively. These subset groups are not mutually exclusive, and the OHT adverse event occurred in a total of 14 patients or 26.9% when combined. Caution should be exercised in comparing percentages across studies, as we have observed varying definitions of IOP-related adverse events. In addition, many larger randomized clinical trials had exclusion criteria that did not allow inclusion of known glaucoma or OHT subjects.
We initially hypothesized that patients with NIPU may be more prone to IOP elevations because uveitis alone can cause elevated IOP. Interestingly, there was no statistically significant difference in change in IOP across all clinical indications ( Figure 1B and Table 2 ). We looked more specifically at the 1.5-month to 2.5-month interval where patients may be most prone to IOP elevations, but again did not find a significant difference. We suspect that this may relate to the slow controlled release of dexamethasone. One retrospective study evaluating Ozurdex for uveitis found 7 instances of increased IOP (defined as .21 mmHg), of 38 eyes and 61 injections, all of which responded to pharmacologic treatment, and none required incisional or laser surgery even if they were previously diagnosed as steroid responders. 15 In a large 3-year randomized study evaluating Ozurdex for DME, 41.5% (among 347 patients) who received the 0.7 mg Ozurdex injection required IOP-lowering medication, and 5 patients (1.5%) required surgery for glaucoma. 13 Our results, albeit smaller in numbers and retrospective, had no instances of elevated IOP after Ozurdex injections for 20 cases of DME.
In our report, there was no difference in IOP adverse events between those who received one compared with multiple Ozurdex injections. The Kaplan-Meier curve suggests that the greatest likelihood of having an IOP elevation is consistent with the greatest IOP measurements in the 1.5-month to 2.5-month interval. We had several patients who received two or more injections (maximum five), and we did not observe a trend or bias toward IOP elevations with a greater number of Ozurdex injections. To support this, three of the seven patients who had both OHT and multiple Ozurdex injections had the OHT event after their first Ozurdex injection. The remaining four patients experienced OHT at the time of subsequent Ozurdex injections. This is consistent with the recent 3-year results of Ozurdex for DME, where the incidence of IOP adverse events did not increase after subsequent treatments, or in Year 2 or 3, and the proportion of patients using IOPlowering medications in the study eye remained similar from year to year. 13 The results indicated that were was no cumulative effect of Ozurdex on IOP which our data supports. For comparison, 1 case series of 12 patients (15 eyes) found 3 instances of elevated IOP that were all responsive to topical therapy alone (one after the first, one after the second, and one after the third intravitreal injection). 16 Differences in pharmacologic and pharmacokinetic profiles of the available intravitreal steroid treatments may account for their differing safety profiles regarding OHT. Dexamethasone, fluocinolone acetonide, and triamcinolone have been shown to activate different patterns of gene expression in human trabecular meshwork cell lines. 17 Dexamethasone differs from triamcinolone in pharmacologic activity, lipid solubility, and delivery requirements. Dexamethasone is less lipophilic and does not accumulate to the same extent in the trabecular meshwork, and therefore may have lower risk of IOP increases. 18, 19 Our findings suggest that Ozurdex may provide a higher benefit-risk ratio than the fluocinolone implant regarding lower incidence of IOP elevation requiring surgery [20] [21] [22] ; however, head-to-head prospective clinical studies would be necessary to directly compare the safety and efficacy of the Ozurdex implant with other intravitreal steroid modalities.
This study has limitations inherent in its uncontrolled and retrospective nature. Selection bias may affect our results because of a treatment bias against Ozurdex implantation in patients with established glaucoma or suspicion of glaucoma. The long-term prognosis of those patients who developed isolated IOP increases is not known, and they should be followed closely for the possibility of development of glaucoma. 23 Key words: dexamethasone, diabetic macular edema, glaucoma, intraocular pressure, intravitreal, ocular hypertension, Ozurdex, retinal vein occlusion, posterior uveitis.
